SEC Company Response from Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654) (ORKA) — May 10, 2017
Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654)
Date: May 10, 2017 · CIK: 0000907654 · Accession: 0001193125-17-166176
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217459
Letter
Acceleration Request
May 10, 2017
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Dorrie Yale
Re:
ARCA biopharma, Inc.
Registration Statement on Form S-3
File No. 333-217459
Acceleration Request
Requested Date: Friday, May 12, 2017
Requested Time: 4:00 P.M. Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-217459) (the “Registration Statement”) to become effective on May 12, 2017, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Brent Fassett of Cooley LLP, counsel to the Registrant, at (720) 566-4025, or in his absence, Nathan Jeffries at (720) 566-4104.
[Signature page follows]
Very truly yours,
ARCA BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
Acceleration Request
May 10, 2017
VIA EDGAR
U.S. Securities and
Exchange Commission
Division of Corporation Finance
100 F
Street, N.E.
Washington, D.C. 20549
Attn:
Dorrie Yale
Re:
ARCA biopharma, Inc.
Registration Statement on Form S-3
File No. 333-217459
Acceleration Request
Requested
Date: Friday, May 12, 2017
Requested
Time: 4:00 P.M. Eastern Daylight Time
Ladies and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take
appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-217459) (the “Registration Statement”) to become effective on May 12, 2017, at 4:00 p.m., Eastern Daylight Time, or
as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Brent Fassett of Cooley LLP, counsel to the Registrant, at
(720) 566-4025, or in his absence, Nathan Jeffries at (720) 566-4104.
[Signature page follows]
Very truly yours,
ARCA BIOPHARMA, INC.
By:
/s/ Brian L. Selby
Brian L. Selby
Vice President,
Finance
cc: Brent Fassett, Cooley LLP